Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.15.6137

Serum Adiponectin but not Leptin at Diagnosis as a Predictor of Breast Cancer Survival  

Lee, Sang-Ah (Department of Preventive Medicine, Kangwon National University School of Medicine)
Sung, Hyuna (Department of Biomedical Sciences, Seoul National University College of Medicine)
Han, Wonshik (Department of Surgery, Seoul National University College of Medicine)
Noh, Dong-Young (Department of Surgery, Seoul National University College of Medicine)
Ahn, Sei-Hyun (Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center)
Kang, Daehee (Department of Biomedical Sciences, Seoul National University College of Medicine)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.15, 2014 , pp. 6137-6143 More about this Journal
Abstract
Limited numbers of epidemiological studies have examined the relationship between adipokines and breast cancer survival. Preoperative serum levels of obesity-related adipokines (leptin and adiponectin) were here measured in 370 breast cancer patients, recruited from two hospitals in Korea. We examined the association between those adipokines and disease-free survival (DFS). The TNM stage, ER status and histological grade were aslo assessed in relation to breast cancer survival. Elevated adiponectin levels were associated with reduced DFS of breast cancer ($P_{trend}=0.03$) among patients with normal body weight, predominantly in postmenopausal women. There was no association of leptin with breast cancer survival. In conclusion, our study suggests that high levels of adiponectin at diagnosis are associated with breast cancer survival among women with normal body weight.
Keywords
Breast cancer; leptin and adiponectin level at diagnosis; prognosis; serum biomarker;
Citations & Related Records
Times Cited By KSCI : 5  (Citation Analysis)
연도 인용수 순위
1 Miyoshi Y, Funahashi T, Kihara S, et al (2003). Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res, 9, 5699-704.
2 Nkhata KJ, Ray A, Schuster TF, et al (2009). Effects of adiponectin and leptin co-treatment on human breast cancer cell growth. Oncol Rep, 21, 1611-9.
3 Oh SW, Park CY, Lee ES, et al (2011). Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study. Breast Cancer Res, 13, 34.
4 Ollberding NJ, Kim Y, Shvetsov YB, et al (2013). Prediagnostic leptin, adiponectin, C-reactive protein, and the risk of postmenopausal breast cancer. Cancer Prev Res (Phila), 6, 188-95.   DOI
5 Pajvani UB, Hawkins M, Combs TP, et al (2004). Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem, 279, 12152-62.   DOI
6 Petridou E, Papadiamantis Y, Markopoulos C, et al (2000). Leptin and insulin growth factor I in relation to breast cancer (Greece). Cancer Causes Control, 11, 383-8.   DOI
7 Porter GA, Inglis KM, Wood LA, et al (2006). Effect of obesity on presentation of breast cancer. Ann Surg Oncol, 13, 327-32.   DOI   ScienceOn
8 Ray A, Nkhata KJ, Cleary MP (2007). Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status. Int J Oncol, 30, 1499-509.
9 Rock CL, Flatt SW, Laughlin GA, et al (2008). Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer. Cancer Epidemiol Biomarkers Prev, 17, 614-20.   DOI
10 Stattin P, Soderberg S, Biessy C, et al (2004). Plasma leptin and breast cancer risk: a prospective study in northern Sweden. Breast Cancer Res Treat, 86, 191-6.   DOI   ScienceOn
11 Stuckey A (2011). Breast cancer: epidemiology and risk factors. Clin Obstet Gynecol, 54, 96-102.   DOI
12 Sung H, Choi JY, Lee SA, et al (2012). The association between the preoperative serum levels of lipocalin-2 and matrix metalloproteinase-9 (MMP-9) and prognosis of breast cancer. BMC Cancer, 12, 193.   DOI
13 Sweeney C, Blair CK, Anderson KE, et al (2004). Risk factors for breast cancer in elderly women. Am J Epidemiol, 160, 868-75.   DOI   ScienceOn
14 Tworoger SS, Eliassen AH, Kelesidis T, et al (2007). Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab, 92, 1510-16.   DOI
15 Vona-Davis L, Rose DP (2007). Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer, 14, 189-206.   DOI   ScienceOn
16 Chen DC, Chung YF, Yeh YT, et al (2006). Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett, 237, 109-14.   DOI   ScienceOn
17 Waki H, Yamauchi T, Kamon J, et al (2003). Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem, 278, 40352-63.   DOI   ScienceOn
18 Wu MH, Chou YC, Chou WY, et al (2009). Circulating levels of leptin, adiposity and breast cancer risk. Br J Cancer, 100, 578-82.   DOI   ScienceOn
19 Brakenhielm E, Veitonmaki N, Cao R, et al (2004). Adiponectininduced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A, 101, 2476-81.   DOI   ScienceOn
20 Cauley JA, Gutai JP, Kuller LH, et al (1989). The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol, 129, 1120-31.
21 Cleary MP, Maihle NJ (1997). The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer. Proc Soc Exp Biol Med, 216, 28-43.   DOI
22 Fisher FM, Trujillo ME, Hanif W, et al (2005). Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. Diabetologia, 48, 1084-7.   DOI   ScienceOn
23 Cust AE, Stocks T, Lukanova A, et al (2009). The influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study. Breast Cancer Res Treat, 113, 567-76.   DOI
24 Dieudonne MN, Bussiere M, Dos Santos E, et al (2006). Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun, 345, 271-9.   DOI   ScienceOn
25 Dieudonne MN, Machinal-Quelin F, Serazin-Leroy V, et al (2002). Leptin mediates a proliferative response in human MCF7 breast cancer cells. Biochem Biophys Res Commun, 293, 622-8.   DOI   ScienceOn
26 Fontana L, Eagon JC, Trujillo ME, et al (2007). Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes, 56, 1010-3.   DOI   ScienceOn
27 Frankenberry KA, Skinner H, Somasundar P, et al (2006). Leptin receptor expression and cell signaling in breast cancer. Int J Oncol, 28, 985-93.
28 Gadgil A, Roy N, Sankaranarayanan R, et al (2012). Effect of comprehensive breast care on breast cancer outcomes: a community hospital based study from Mumbai, India. Asian Pac J Cancer Prev, 13, 1105-9.   과학기술학회마을   DOI
29 Gaudet MM, Falk RT, Gierach GL, et al (2010). Do adipokines underlie the association between known risk factors and breast cancer among a cohort of United States women? Cancer Epidemiol, 34, 580-6.   DOI
30 Goodwin PJ, Ennis M, Fantus IG, et al (2005). Is leptin a mediator of adverse prognostic effects of obesity in breast cancer? J Clin Oncol, 23, 6037-42.   DOI
31 Gross AL, Newschaffer CJ, Hoffman-Bolton J, et al (2013). Adipocytokines, inflammation, and breast cancer risk in postmenopausal women: a prospective study. Cancer Epidemiol Biomarkers Prev, 22, 1319-24.   DOI
32 Gulcelik MA, Colakoglu K, Dincer H, et al (2012). Associations between adiponectin and two different cancers: breast and colon. Asian Pac J Cancer Prev, 13, 395-8.   과학기술학회마을   DOI   ScienceOn
33 Haghighat S, Akbari ME, Ghaffari S, et al (2012). Standardized breast cancer mortality rate compared to the general female population of Iran. Asian Pac J Cancer Prev, 13, 5525-8.   과학기술학회마을   DOI   ScienceOn
34 Harris HR, Tworoger SS, Hankinson SE, et al (2011). Plasma leptin levels and risk of breast cancer in premenopausal women. Cancer Prev Res, 4, 1449-56.   DOI
35 Hou WK, Xu YX, Yu T, et al (2007). Adipocytokines and breast cancer risk. Chin Med J, 120, 1592-6.
36 Hu X, Juneja SC, Maihle NJ, et al (2002). Leptin--a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst, 94, 1704-11.   DOI   ScienceOn
37 Jarde T, Caldefie-Chezet F, Goncalves-Mendes N, et al (2009). Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endocr Relat Cancer, 16, 1197-210.   DOI
38 Karimi N, Roshan VD (2013). Change in adiponectin and oxidative stress after modifiable lifestyle interventions in breast cancer cases. Asian Pac J Cancer Prev, 14, 2845-50.   과학기술학회마을   DOI
39 Llanos AA, Dumitrescu RG, Marian C, et al (2012). Adipokines in plasma and breast tissues: associations with breast cancer risk factors. Cancer Epidemiol Biomarkers Prev, 21, 1745-55.   DOI   ScienceOn
40 Lee JJ, Park HY (2009). The timing of recurrence dependent on menopausal status after surgery for breast cancer. J Korean Surg Soc, 77, 75-81.   과학기술학회마을   DOI
41 Loi S, Milne RL, Friedlander ML, et al (2005). Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev, 14, 1686-91.   DOI   ScienceOn
42 Mantzoros C, Petridou E, Dessypris N, et al (2004). Adiponectin and breast cancer risk. J Clin Endocrinol Metab, 89, 1102-7.   DOI   ScienceOn
43 Mantzoros CS, Bolhke K, Moschos S, et al (1999). Leptin in relation to carcinoma in situ of the breast: a study of premenopausal cases and controls. Int J Cancer, 80, 523-6.   DOI
44 McTiernan A (2005). Obesity and cancer: the risks, science, and potential management strategies. Oncology, 19, 871-81.
45 Maccio A, Madeddu C (2011). Obesity, inflammation, and postmenopausal breast cancer: therapeutic implications. ScientificWorldJournal, 11, 2020-36.   DOI